The biopotency of six preparations of thyrotrophin (TSH) has been compared in a highly sensitive in vitro porcine thyroid cell bioassay using iodide uptake as an endpoint. Three of these preparations were of human origin and three derived from bovine pituitary tissue. One human TSH preparation, the 2nd International Reference Preparation, 80/558, was used to calibrate the other five. The log dose-log response curves for all preparations were sigmoidal in shape. For the purpose of evaluation the central linear portions of the curves were compared. With all preparations the slopes in this region were very similar. The relative biopotencies of the bovine preparations (unit: unit) were at least five times those of the human standards when measured using the porcine thyroid cell bioassay. These findings emphasise the need to control the TSH standards employed in a variety of bioassays, particularly those used for between-laboratory comparison.
Biological assays for thyroid stimulators have become increasingly used over the last decade. I ] With the exception of the cytochemical bioassay none of these is suitable for measuring plasma thyrotrophin (thyroid stimulating hormone; TSH) in the physiological range. Immunoassay therefore remains the only viable option when monitoring clinical thyroid status. However in vitro biological assays can be used to assess and compare the biopotency of TSH/thyroid stimulator preparations. Some of these bioassaysv' allow a high through-put of samples making it possible to assess several preparations within one experiment and to achieve rapid, reproducible results. Furthermore in vitro biological assay potency estimates may be used to compare and complement estimates of potency from other assays, e.g. immunoassays, providing valuable information on standardisation.
With these objectives in view, the aim of the present study was to assess the biopotency of the newest TSH standard for immunoassay, 2nd International Reference Preparation (lRP) 80/558, and to compare this with five other TSH • Present address: ICI pIc,Central Toxicology Laboratory, Alderley Park, Macclesfield, CheshireSK I0 4TJ,
UK.
Correspondence: Dr A Lambert. preparations currently used in some laboratories. Of these one (1st IRP 68/38) has been extensively used as an immunoassay standard whilst the remaining four (MRCA 63/14, bovine TSH 53/ II, Armour Thytropar and Sigma TSH) have been widely used in biological assays.
We now report a comparison of these TSH preparations using an in vitro porcine thyroid cell bioassay.'
Materials and methods
The preparation of primary cultures of porcine thyrocytes has been described in detail elsewhere.' Briefly, porcine thyroid glands were obtained from the local abattoir and transported to the laboratory on ice within I h of slaughter. They were chopped into I rnm' pieces under sterile conditions and the tissue pieces were washed twice in Hank's balanced salt solution (Flow Labs, Irvine, Strathclyde, UK) containing 200000U/L penicillin 0·2 g/L streptomycin and 2·5 mg/L amphotericin B (medium I). The tissue was dispersed at 37°C in medium I containing 0·25% (w/v) Dispase II (Boehringer Mannheim, Lewes, UK) and 0·05% (w/v) collagenase (grade II, Flow Labs) for 1·25 h. The cells were filtered and washed three times in Eagle's minimal essen- . Finally they were filtered through a 120 11m2 stainless-steel mesh. Viable cell yields, assessed by trypan blue exclusion, were> 6 x 10 6 cells/g fresh tissue and viability was always better than 85°1.,.
The cell suspension was diluted to 2 x 10 6 cells/ ml in medium 2 and 500 JlI/well were added to 24 well culture plates previously treated with 2 mgj ml poly-r-lysine hydrobromide. The cells were then kept in an incubator at 3TC under humidified 5% CO 2: 95% air overnight (20 h). After overnight culture the medium was replaced with HBIOI (HANA Media Inc., Berkeley, California, USA) supplemented with 20 mrnol/L HEPES, I rnmol/L sodium pyruvate, 2 rnmol/L L-glutamine, 10 mrnol/L sodium bicarbonate, 30 Jlmol/L hydrocortisone hemisuccinate and 50 mg/L gentamycin sulphate and increasing concentrations of the standard TSH preparation [bovine TSH (Sigma, Thytropar, 53/11) or human TSH (68/ 38,80/558, 63/14)]. Incubation was then continued for 3·5 days.
After this period, radioactive iodide (Jl2S, 0·2 JlCi/well in 3·6 Jlmol/L NaI) was administered to the cells and the incubation continued for 6 h.' The medium was removed and the cells washed briefly with ice-cold Hank's balanced salt solution. One millilitre of 100 rnmol/L NaOH was then added to each well. The cells were solubilised overnight and the total 125iodide in the cell fraction was assessed using a gamma counter (total iodide uptake). 
The doses were 0,1, 0'5, 1,5 for the bovine TSH preparations and 0,5, 1,5, 10 for the human TSH preparations. porcine thyrocytes cultured for 3·5 days in serumfree HBIOI medium is shown in Fig. I . Plots of the log dose-log response lines gave sigmoid curves with flattened regions at either end. For comparison of slopes consideration was restricted to doses with responses in the linear region of the curve extending over a common response range. These doses were 0,5, I, 5 and 10 units for preparations 80/558, 68/38 and 63/14 and 0,1, O' 5, I and 5 for preparations 53/11, Sigma and Thytropar. Slopes of the log dose-log response lines in this region for the various TSH preparations are given in Table I . Differences among slopes relative to deviations of mean log response about the fitted lines were not significant (P> 0'05). Estimates of the relative potency of the various preparations calculated as the displacement of the log dose-log response lines in the central common response range are shown in Table 2 . Of the human TSH preparations tested, 80/558 and 63/38 appear to be equipotent although 63/14 may be slightly less potent. On the basis of the analysis described, the bovine TSH preparations are at least 5 times more potent (unit/unit) than the human TSH preparations.
Discussion
In this study we have reported the findings of the biopotencies of six TSH preparations estimated using an in vitro bioassay based on porcine thyroid cells.' The TSH-stimulated iodide uptake response of such cells was reliable and showed good agreement between experiments. The slopes of the log dose-log response lines in the central linear region were similar for all TSH preparations tested (P > 0,05). The estimates ofbiopotency using human TSH 80/558 as the reference standard clearly indicated that the bovine TSH preparations were at least 5 times more potent, unit for unit, than the human TSH standards. The data obtained in this study will incorporate differences in the relative stabilities of the individual TSH preparations. Bovine TSH standard 53/11 was prepared from a crude pituitary extract in 1953 in tablet form and stored for over 30 years at -IQUe. 7 The other bovine TSH preparations, although more modern in manufacture, were similarly prepared and standardized. All the bovine preparations were standardized against the United States Pharmacopeia (USP) Thyro-tropin Reference Standard using in vivo assays based on iodide metabolism in the chick (Armour Pharmaceuticals information sheet on Thytropar). One USP unit was defined as the activity of 20 mg of the Reference Standard.
The monitoring of the potency of human and bovine TSH with porcine thyroid cells may introduce problems of species specificity. Bidey et al.' using the rat FRTL-5 cell line compared bovine TSH 'Thytropar' against human TSH 63/14 and reported a potency ratio of 2: I (bovine: human). Rapoport et al.,s using the same TSH preparations, found potency ratios of 12: 1 for canine and 2: 1 for human thyroid cells. Such differences were taken to indicate that there may be differences in structural determinants on the TSH receptor. In studies where a comparison between human and porcine thyroid cell membranes was made using thyroid-binding immunoglobulins, there were no apparent differences between species." Kermode et al," carried out similar studies of bovine and human TSH binding to human thyroid membranes and concluded that the binding of either species of TSH was very similar. These findings suggest that species specificity of response may be a problem in some assays but a considerably more rigorous assay design would be needed to highlight this. Therefore, although these potency estimates remain relative, it is clear that comparison of results between research workers should be made using strictly similar assay conditions. This suggestion is further supported by the international collaborative study organised by the National Institute for Biological Standards and ControlI I in which the cytochemical bioassay for TSH gave a biopotency estimate almost 20 times that of both an in vitro bioassay (cyclic AMP production) and the McKenzie in vivo bioassay." The discrepancy between the results of Bidey et al" and our own, potency ratios of 2: I compared to 5: I for 'Thytropar': 68/38 respectively, remains interesting and may partly be explained by the differences in assay sensitivities to TSH. The in vitro porcine thyroid cell iodide uptake bioassay is at least 50 times more sensitive than the FRTL-5 cell bioassay with cAMP as end point (0,1 mUlL compared to 5 mUlL for 'Thytropar'). A bioassay responsive to low TSH activities may recognise a spectrum of heterogenous populations of extracted pituitary TSH. Such heterogenous forms of extracted glycoprotein hormones have been shown previously for both human LHl3 and FSH. 14 Despite the finding that bovine TSH preparations are relatively more biopotent than human preparations there remains the possibility that the bovine materials may contain more TSH (mole for mole) than the human standards. The methods of preparation and particularly standardisation of bovine materials (e.g. Mussett and Perry' and Armour Pharmaceuticals information sheet on 'Thytropar') suggest that this may be the case. Clearly, therefore, it is imperative that comparisons of the biopotency of TSH preparations between different assay types are made using a standard ofTSH derived from a common source such as human TSH 80/558.
In conclusion, the present study demonstrates that the in vitro porcine thyroid cell bioassay can be used to assess the biopotency of both bovine and human TSH preparations. Bovine preparations appear biologically more potent. An exact interpretation of these findings cannot be made due to the nature of the manufacture of the various TSH preparations and their standardisation. However the bioassay reported here has shown that TSH preparations similarly standardised human TSH standards, for example gave results in close agreement. Problems of species specificity and heterogeneity of TSH preparations remain to be resolved.
